Cargando…

Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study

The antibiotic spectrum is not reflected in conventional antimicrobial metrics. Days of antibiotic spectrum coverage (DASC) is a novel quantitative metric for antimicrobial consumption developed with consideration of the antibiotic spectrum. However, there were no data regarding disease and pathogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Maeda, Masayuki, Nakata, Mari, Naito, Yuika, Yamaguchi, Kozue, Yamada, Kaho, Kinase, Ryoko, Takuma, Takahiro, On, Rintaro, Tokimatsu, Issei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774691/
https://www.ncbi.nlm.nih.gov/pubmed/36551402
http://dx.doi.org/10.3390/antibiotics11121745
_version_ 1784855470008172544
author Maeda, Masayuki
Nakata, Mari
Naito, Yuika
Yamaguchi, Kozue
Yamada, Kaho
Kinase, Ryoko
Takuma, Takahiro
On, Rintaro
Tokimatsu, Issei
author_facet Maeda, Masayuki
Nakata, Mari
Naito, Yuika
Yamaguchi, Kozue
Yamada, Kaho
Kinase, Ryoko
Takuma, Takahiro
On, Rintaro
Tokimatsu, Issei
author_sort Maeda, Masayuki
collection PubMed
description The antibiotic spectrum is not reflected in conventional antimicrobial metrics. Days of antibiotic spectrum coverage (DASC) is a novel quantitative metric for antimicrobial consumption developed with consideration of the antibiotic spectrum. However, there were no data regarding disease and pathogen-specific DASC. Thus, this study aimed to evaluate the DASC trend in patients with bloodstream infections (BSIs). DASC and days of therapy (DOT) of in-patients with positive blood culture results during a 2-year interval were evaluated. Data were aggregated to calculate the DASC, DOT, and DASC/DOT per patient stratified by pathogens. During the 2-year study period, 1443 positive blood culture cases were identified, including 265 suspected cases of contamination. The overall DASC, DASC/patient, DOT, DOT/patient, and DASC/DOT metrics were 226,626; 157.1; 28,778; 19.9; and 7.9, respectively. A strong correlation was observed between DASC and DOT, as well as DASC/patient and DOT/patient. Conversely, DASC/DOT had no correlation with other metrics. The combination of DASC and DOT would be a useful benchmark for the overuse and misuse evaluation of antimicrobial therapy in BSIs. Notably, DASC/DOT would be a robust metric to evaluate the antibiotic spectrum that was selected for patients with BSIs.
format Online
Article
Text
id pubmed-9774691
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97746912022-12-23 Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study Maeda, Masayuki Nakata, Mari Naito, Yuika Yamaguchi, Kozue Yamada, Kaho Kinase, Ryoko Takuma, Takahiro On, Rintaro Tokimatsu, Issei Antibiotics (Basel) Article The antibiotic spectrum is not reflected in conventional antimicrobial metrics. Days of antibiotic spectrum coverage (DASC) is a novel quantitative metric for antimicrobial consumption developed with consideration of the antibiotic spectrum. However, there were no data regarding disease and pathogen-specific DASC. Thus, this study aimed to evaluate the DASC trend in patients with bloodstream infections (BSIs). DASC and days of therapy (DOT) of in-patients with positive blood culture results during a 2-year interval were evaluated. Data were aggregated to calculate the DASC, DOT, and DASC/DOT per patient stratified by pathogens. During the 2-year study period, 1443 positive blood culture cases were identified, including 265 suspected cases of contamination. The overall DASC, DASC/patient, DOT, DOT/patient, and DASC/DOT metrics were 226,626; 157.1; 28,778; 19.9; and 7.9, respectively. A strong correlation was observed between DASC and DOT, as well as DASC/patient and DOT/patient. Conversely, DASC/DOT had no correlation with other metrics. The combination of DASC and DOT would be a useful benchmark for the overuse and misuse evaluation of antimicrobial therapy in BSIs. Notably, DASC/DOT would be a robust metric to evaluate the antibiotic spectrum that was selected for patients with BSIs. MDPI 2022-12-02 /pmc/articles/PMC9774691/ /pubmed/36551402 http://dx.doi.org/10.3390/antibiotics11121745 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Maeda, Masayuki
Nakata, Mari
Naito, Yuika
Yamaguchi, Kozue
Yamada, Kaho
Kinase, Ryoko
Takuma, Takahiro
On, Rintaro
Tokimatsu, Issei
Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study
title Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study
title_full Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study
title_fullStr Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study
title_full_unstemmed Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study
title_short Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study
title_sort days of antibiotic spectrum coverage trends and assessment in patients with bloodstream infections: a japanese university hospital pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774691/
https://www.ncbi.nlm.nih.gov/pubmed/36551402
http://dx.doi.org/10.3390/antibiotics11121745
work_keys_str_mv AT maedamasayuki daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy
AT nakatamari daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy
AT naitoyuika daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy
AT yamaguchikozue daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy
AT yamadakaho daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy
AT kinaseryoko daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy
AT takumatakahiro daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy
AT onrintaro daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy
AT tokimatsuissei daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy